Re: Statin Drugs and Risk of Advanced Prostate Cancer (PC) von Schröder, F.H

Volltext

Prostate cancer: Trends in incidence, survival and mortality in the Netherlands, 1989–2006 von Cremers, R.G.H.M, Karim-Kos, H.E, Houterman, S, Verhoeven, R.H.A, Schröder, F.H, van der Kwast, T.H, Kil, P.J.M, Coebergh, J.W.W, Kiemeney, L.A.L.M

Volltext

S13 PSA screening in early detection of prostate cancer von Schröder, F.H

Volltext

Blinded and uniform causes of death verification in cancer screening: A major influence on the outcome of a prostate cancer screening trial? von Otto, S.J, van Leeuwen, P.J, Hoekstra, J.W, Merckelbach, J.W, Blom, J.H.M, Schröder, F.H, Roobol, M.J, de Koning, H.J

Volltext

Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins von van Brussel, J.P, van Steenbrugge, G.J, Romijn, J.C, Schröder, F.H, Mickisch, G.H.J

Volltext

Prostate cancer specific mortality in the ERSPC trial: What is the role of screening result and adherence von Wetterauer, C., Remmers, S., Hugosson, J., Tammela, T., Zappa, M., Nelen, V., Lujan, M., Denis, L.J., Paez, A., Puliti, D., Arnaud, V., Rebillard, X., Ansrud Godtman, R., Bangma, C., Schröder, F.H., Auvinen, A., Manka, L., Prause, L.W., Seifert, H.H., Wyler, S.F., Roobol, M.J., Kwiatkowski, M.

Volltext

The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer von Gosselaar, C., Kranse, R., Roobol, M.J., Roemeling, S., Schröder, F.H.

Volltext

Screening for prostate cancer von Postma, R., Schröder, F.H.

Volltext

Screening for prostate cancer: have you had your cholesterol measured? von Schroder, F.H.

Volltext

The story of the European Randomized Study of Screening for Prostate Cancer von Schröder, F.H., Denis, L.J., Roobol, M.

Volltext

Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands) von Roobol, M.J., Kirkels, W.J., Schröder, F.H.

Volltext

1013 PREDICTING FAVOURABLE PATHOLOGICAL OUTCOME IN PATIENTS WITH CLINICAL HIGH RISK PROSTATE CANCER. A NOVEL NOMOGRAM BASED ON A MULTI-INSTITUTIONAL ANALYSIS von Briganti, A, Spahn, M, Joniau, S, Gontero, P, Montorsi, F, Marchioro, G, Tombal, B, Frohneberg, D, Isbarn, H, Bangma, C.H, Schroder, F.H, Kneitz, B, Bader, P, Graefen, M, Tizzani, A, Van Poppel, H

Volltext

The Future of Endocrine Treatment in Early Prostate Cancer: Concluding Remarks von Schröder, F.H.

Volltext

The European Randomized Study of Screening for Prostate Cancer (ERSPC) von SCHRÖDER, F.H., BANGMA, C.H.

Volltext

Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men von Postma, R., Schröder, F.H., van der Kwast, T.H.

Volltext

Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM) von Roobol, M.J, Kranse, R, de Koning, H.J, Schröder, F.H

Volltext

European Randomized Study of Screening for Prostate Cancer: achievements and presentation von Roobol, M.J., Schröder, F.H.

Volltext

1 Screening for prostate cancer: Results of the Rotterdam section of the European Randomized study of Screening for Prostate Cancer (ERSPC) von Roobol, M.J, Bangma, C.H, Schröder, F.H

Volltext

Biomarkers and screening for prostate cancer von Schröder, F.H.

Volltext

115 Gleason score reclassification of men with classical Gleason score ≤6 who eventually died of prostate cancer in the ERSPC Rotterdam von Bokhorst, L.P, Kweldam, C.F, Bangma, C.H, Schröder, F.H, Van Der Kwast, T.H, Leenders, G.J.L.H, Roobol, M.J

Volltext